Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative Sintilimab with Chemotherapy for Borderline Resectable Esophageal Squamous Cell Carcinoma
NCT04548440Phase 2Completed
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Aug 2020; status: completed.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04548440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548440.